Keensight Capital, a private equity manager dedicated to pan-European Growth Buyout investments, has invested in CatSci Ltd, a Contract Research Organisation (CRO) supporting top tier global pharmaceutical companies around the world.
Keensight Capital will invest alongside the founders, senior management, and employees.
Headquartered in the United Kingdom, CatSci was formed in December 2010 from a spin-out of AstraZeneca’s Catalyst Screening Facility by five founders, including current co-owners Dr Ross Burn and Dr Simon Tyler, now CEO and COO, respectively.
